A rendering of 222 Jacobs St. at Cambridge Crossing. Photo Credit: Nate Atwater A rendering of 222 Jacobs St. at Cambridge Crossing. Photo Credit: Nate Atwater

CAMBRIDGE, MA—Cerevel Therapeutics has signed a 59,865-square-foot lease with DivcoWest at its Cambridge Crossing complex. The deal brings the third commercial building at the complex—222 Jacobs St.—to fully leased.

The biopharmaceutical company will join Philips North America at 222 Jacobs St. in 2020. Philips North American announced it had signed a 243,000-square-foot lease at Cambridge Crossing in January 2018 and would relocate its North American headquarters to the complex that lies at the intersection of Cambridge, Somerville and Boston.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

John Jordan

John Jordan is a veteran journalist with 36 years of print and digital media experience.

More from this author



Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2022 ALM Global, LLC. All Rights Reserved.